schizophrenia

Apr 08 2025

Uncategorized

Hope, caution for Washington state patients ‘first in line’ for new schizophrenia drug

by Clinical Editor

No Comments

Cobenfy was approved by the Food and Drug Administration in fall 2024 and represents the first novel approach in decades to treating schizophrenia, which affects an estimated 3.7 million American...

Apr 07 2025

Uncategorized

Hope, caution for WA patients ‘first in line’ for new schizophrenia drug

by Clinical Editor

No Comments

Washingtonians with schizophrenia are curious about a recently FDA-approved drug to treat their symptoms but much is unknown about how well it works.

Apr 07 2025

Uncategorized

Insights on Schizophrenia-Linked Hoarding

by Clinical Editor

No Comments

A recent study of the hoarding phenomenon within schizophrenia spectrum disorders highlights the need for nuanced assessments and reconsideration of diagnostic classifications.

Apr 06 2025

Uncategorized

Glutamate and Psychiatric Disorders

by Clinical Editor

No Comments

Discover how the brain’s most abundant neurotransmitter, glutamate, is revolutionizing psychiatry and offering new hope for depression, bipolar disorder, and more.

Apr 05 2025

Uncategorized

New global guidelines to treat schizophrenia

by Clinical Editor

No Comments

New guidelines have been developed for the treatment of schizophrenia through a collaborative effort of international experts from 30 countries. The recommendations are published in The Lancet …

Apr 04 2025

Uncategorized

Teva’s Novel Schizophrenia Drug Candidate Demonstrates High Patient, Provider Satisfaction in Phase III Trial Survey

by Clinical Editor

No Comments

Results from the SOLARIS trial survey showed that over 92% of patients, 87% of nurses, and 72% of physicians expressed satisfaction with TEV-‘749’s initiation regimen, dosing schedule, and overall …

Apr 04 2025

Uncategorized

Hallucinogen-related ER visits linked to higher risk of schizophrenia, study finds

by Clinical Editor

No Comments

People who visit emergency rooms after using hallucinogenic drugs may face a higher risk of developing schizophrenia spectrum disorders, a new study published in JAMA Psychiatry suggests.

Apr 03 2025

Uncategorized

The dark side of psychiatry – how it has been used to control societies

by Clinical Editor

No Comments

In his new book, No More Normal, psychiatrist Alastair Santhouse recalls an experience from the 1980s when he was a university student in the UK helping deliver supplies to “refuseniks”...

Apr 03 2025

Uncategorized

Cognitive Markers and Functional Connectivity in Schizophrenia and High-Risk Individuals

by Clinical Editor

No Comments

The following is a summary of “Abnormalities in cognitive-related functional connectivity can be used to identify patients with schizophrenia and individuals in clinical high-risk,” published in the …

Apr 02 2025

Uncategorized

Mental health advocate speaks on how to help people experiencing psychosis

by Clinical Editor

No Comments

One mental health advocate is emphasizing the importance of treatment after the death of a Cedar Rapids man with schizophrenia.